Bone Metastasis in Solid Tumors Market Expected to Experience Steady Growth and Market Evolution by 2036 - DelveInsight

DelveInsight's "Bone Metastasis in Solid Tumor Market Insights, Epidemiology and Market Forecast - 2036" report offers an in-depth understanding of Bone Metastasis in Solid Tumors, historical and forecasted epidemiology, as well as the Bone Metastasis in Solid Tumor market trends in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Get more details on the Bone Metastasis in Solid Tumor Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/bone-metastasis-in-solid-tumors-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Key Facts of the Bone Metastasis in Solid Tumor Market Report

• In June 2026, Exelixis continued to expand the clinical evaluation of Cabozantinib across advanced solid tumors with high bone metastatic burden, reinforcing its role in targeting the tumor-bone microenvironment through dual inhibition of c-MET and VEGFR2 signaling pathways, and supporting ongoing combination strategies with immune checkpoint inhibitors and bone-targeted agents.
• In March 2026, emerging translational and real-world evidence further supported cabozantinib's utility in reducing skeletal-related events and disease progression in patients with bone-metastatic renal cell carcinoma and prostate cancer.
• The Bone Metastasis in Solid Tumors market is expected to evolve significantly over the forecast period (2026-2036), driven by rising cancer incidence, improved survival rates, increasing prevalence of metastatic disease, and the development of targeted therapies to prevent skeletal complications and improve outcomes.
• Bone metastasis frequency varies substantially by cancer type: a study of autopsy cases from the Shikoku Cancer Center in Japan (Shibata et al., 2016) found rates reaching as high as 75% in breast and prostate cancers and as low as 22% in stomach and colon cancers.
• Per Huang et al. (2020), the rate of bone metastases was 23.19% in small cell lung cancer (SCLC), 22.50% in NSCLC (NOS/others), 20.28% in adenocarcinoma, 8.44% in squamous cell carcinoma of the lung, and 4.11% in bronchioloalveolar carcinoma (NSCLC-BAC).
• According to the American Cancer Society (ACS), about 400,000 new cases of malignant bone metastasis are diagnosed in the United States each year.
• Metastatic bone disease is commonly observed in breast (70%), prostate (85%), lung (40%), and kidney (40%) cancers, as reported by Coleman et al. (2020).
• Per ACS, the incidence of advanced malignant tumors with bone metastasis ranges from 30-75%, and is especially common in patients with advanced prostate cancer and breast cancer.
• According to Hernandez et al. (2015), approximately 330,000 patients aged 18 years and older were living with solid tumors and bone metastases in 2012.
• The United States accounted for the largest share of the Bone Metastasis in Solid Tumor market in 2025 among the 7MM during the study period.
• Key Bone Metastasis in Solid Tumor Companies: Exelixis, Actuate Therapeutics, Ipsen, Novartis, Amgen, AstraZeneca, Bayer, Pfizer, Eli Lilly and Company, Merck & Co., Bristol Myers Squibb, Novocure, Fusion Pharmaceuticals, Actinium Pharmaceuticals, Telix Pharmaceuticals, and others.
• Key Bone Metastasis in Solid Tumor Therapies: Cabozantinib (CABOMETYX), Denosumab (XGEVA), Zoledronic Acid (ZOMETA), Radium-223 (XOFIGO), and others.
• The Bone Metastasis in Solid Tumors market is expected to surge due to the rising burden of skeletal metastases and the emergence of novel bone microenvironment-directed and radiopharmaceutical therapies during the forecast period.

Bone Metastasis in Solid Tumors Overview

Bone metastasis in solid tumors occurs when cancer cells spread from a primary tumor to the bone, forming secondary malignant lesions within the skeletal system. It is a common complication of advanced cancers such as breast, prostate, lung, renal cell carcinoma, and thyroid cancer. The process involves complex tumor-bone interactions that drive osteoclastic or osteoblastic activity, leading to bone destruction and remodeling. Bone metastases can result in significant morbidity through skeletal-related events (SREs), including pain, pathological fractures, spinal cord compression, hypercalcemia, and reduced mobility, severely impacting quality of life and increasing healthcare burden. Although generally incurable, advances in systemic therapies and supportive care have improved disease control and survival outcomes.

To know in detail about the Bone Metastasis in Solid Tumor market outlook, drug uptake, treatment scenario, and epidemiology trends, click here:
https://www.delveinsight.com/report-store/bone-metastasis-in-solid-tumors-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Bone Metastasis in Solid Tumors Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps recognize the causes of current and forecasted trends by exploring numerous studies and the views of key opinion leaders. The section also provides a detailed analysis of the diagnosed patient pool and future trends.

Bone Metastasis in Solid Tumors Epidemiology Segmentation

• Total Diagnosed Prevalent Cases of Bone Metastasis in Solid Tumors
• Total Cases of Bone Metastasis by Solid Tumor Type

Bone Metastasis in Solid Tumors Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of potential drugs recently launched in the Bone Metastasis in Solid Tumor market or expected to launch during the study period. The analysis covers market uptake by drugs, patient uptake by therapy, and sales of each drug.
Therapy uptake is expected to vary across bone-targeted agents, systemic anticancer therapies, radiotherapy, radiopharmaceuticals, and emerging targeted treatments over the forecast period. Bone-targeted therapies such as XGEVA and ZOMETA are expected to remain the mainstay of treatment due to their established efficacy in reducing skeletal-related events, alleviating bone pain, and preserving skeletal integrity. A gradual shift in treatment patterns is expected with increasing adoption of therapies such as CABOMETYX that target both tumor growth and the bone metastatic microenvironment, alongside investigational agents like elraglusib.
The report also covers the Bone Metastasis in Solid Tumor Pipeline Development Activities, providing insights into different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics, along with recent collaborations, licensing, and other developments.

Bone Metastasis in Solid Tumors Therapies and Key Companies

• Denosumab (XGEVA): Amgen
• Cabozantinib (CABOMETYX): Exelixis
• Zoledronic Acid (ZOMETA): Novartis
• Radium-223 (XOFIGO): Bayer

Discover more about therapies set to grab major Bone Metastasis in Solid Tumor market share:
https://www.delveinsight.com/report-store/bone-metastasis-in-solid-tumors-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Bone Metastasis in Solid Tumors Market Drivers

• Rising burden of bone metastases in solid tumors, driven by the increasing incidence of advanced breast, prostate, lung, kidney, and thyroid cancers combined with improved cancer survival from advances in systemic therapies, leading to a larger patient population developing skeletal metastases.
• Growing opportunities for targeted and bone microenvironment therapies, as advances in understanding tumor-bone interactions, osteoclast activity, and bone microenvironment biology drive the development of novel agents designed to disrupt metastatic colonization and tumor-driven bone remodeling.
• Increasing adoption of radiopharmaceutical and precision oncology approaches, enabling targeted treatment delivery, biomarker-guided therapy selection, and improved disease control with reduced off-target effects.
• An evolving competitive landscape, with companies such as Exelixis, Novartis, Amgen, Bayer, AstraZeneca, Pfizer, and Bristol Myers Squibb developing next-generation bone-targeted therapies, radioligand treatments, immunotherapies, and combination strategies.

Bone Metastasis in Solid Tumors Market Barriers

• Limited availability of therapies that can prevent, delay, or reverse bone metastasis progression, with most current treatments focused on symptom control and reducing SREs rather than modifying the underlying disease.
• Bone-targeted agents such as bisphosphonates and denosumab reduce complications but do not eliminate metastatic disease or meaningfully improve overall survival in most patients, leaving persistent unmet need for disease-modifying options.
• Limited options for patients with advanced, resistant, or rapidly progressing bone metastases who continue to experience symptoms despite standard-of-care treatment, along with an absence of robust biomarkers and predictive tools for personalized treatment selection and monitoring.

Scope of the Bone Metastasis in Solid Tumors Market Report

• Study Period: 2022-2036
• Forecast Period: 2026-2036
• Coverage: 7MM
• Key Bone Metastasis in Solid Tumor Companies: Exelixis, Actuate Therapeutics, Ipsen, Novartis, Amgen, AstraZeneca, Bayer, Pfizer, Eli Lilly and Company, Merck & Co., Bristol Myers Squibb, Novocure, Fusion Pharmaceuticals, Actinium Pharmaceuticals, Telix Pharmaceuticals, and others.
• Key Bone Metastasis in Solid Tumor Therapies: Cabozantinib (CABOMETYX), Denosumab (XGEVA), Zoledronic Acid (ZOMETA), Radium-223 (XOFIGO), and others.
• Bone Metastasis in Solid Tumor Therapeutic Assessment: Current marketed and emerging therapies.
• Bone Metastasis in Solid Tumor Market Dynamics: Market drivers and market barriers.
• Competitive Intelligence Analysis: SWOT analysis, Conjoint analysis, Market entry strategies.
• Bone Metastasis in Solid Tumor Unmet Needs, KOL's views, Analyst's views, Market Access and Reimbursement.

Table of Contents

1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Forecast Methodology
6. Market Overview
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey
10. Approved Drugs
11. Emerging Drugs
12. Market Analysis (7MM)
13. Unmet Needs
14. SWOT Analysis
15. Key Opinion Leaders (KOL) Views
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.